Three drug families sit at the center of everyday practice, and all three are moving targets. Get them right and a lot of medicine gets easier; get rusty and the second-guessing starts. They’re worth a periodic, deliberate refresh — not because you don’t know them, but because the details shift.
Anticoagulants have changed the most. DOACs have particular dosing by indication and renal function, specific reversal agents, and bridging decisions that trip people up. Keeping the current picture straight — when a DOAC is preferred, when warfarin still wins, how to manage a bleed — is high-stakes and high-yield. Antibiotics demand a working mental model of spectrum and resistance, plus the perennial questions around penicillin-cephalosporin cross-reactivity and stewardship. Antihypertensives reward knowing first-line choices by comorbidity (the diabetic, the patient with heart failure, the pregnant patient) and the contraindications that turn a reasonable choice into a harmful one.
A refresher works best when it puts these side by side and tests you on the distinctions, rather than leaving you to notice a gap only when a patient is in front of you. The Pharmacology Review Course does that across these families and the rest of the high-yield map: 12.5 hours of AAPA Category 1 CME, organized by class, with teaching explanations that reinforce the why. You come out sharper on the medications you reach for most — and you log documented credit doing it. It’s $399.99 for 30 months, with the optional $100–$1,500 Amazon or Apple gift-card add-on.